

Infusion Therapy Order

Patient Name: _____ Date of Birth: _____

Address: _____ Height: _____ Weight: _____

Phone: _____ Allergies: _____

Primary Diagnosis: _____ ICD-10 Code: _____

Requested Infusion Start Date: _____ Frequency: _____

Infusion Location: _____ Duration: _____

Insurance Authorization: _____

Prescriber Information:

Prescriber Name: _____ NPI: _____

Address: _____

Phone: _____ Fax: _____

Prescriber Signature: _____

*****Please use a single line and mark through any orders you do not want if it is pre-checked...The Appointment request is required, but make edits to the Interval and Duration as needed...Please add any additional orders on the last page*****

SJH SPLENECTOMY VACCINES

version 9/6/2022

Appointment Request

		Interval	Defer Until	Duration
☒	SJH ONCBCN INJECTION APPOINTMENT REQUEST			
☒	Injection Appointment Request	Once	S	1 treatment

Status: Future, Expected: S Approximate, Expires: S+365, Sched. Duration: 30 minutes, Sched. Tolerance: Schedule appointment at most 2 days before or at most 2 days after

Appointment Request (continued)

		Interval	Defer Until	Duration
☒	SJH ONCBCN INJECTION APPOINTMENT REQUEST			
☒	Injection Appointment Request	Once	S+56	1 treatment
Status: Future, Expected: S Approximate, Expires: S+365, Sched. Duration: 30 minutes, Sched. Tolerance: Schedule appointment at most 2 days before or at most 2 days after				

Medications

		Interval	Defer Until	Duration
☒	SJH ONCBCN THERAPY SPLENECTOMY VACCINES DAY 1			
☒	meningococcal A conjugate vaccine (MENVEO) injection 0.5 mL	Once	S	1 treatment
0.5 mL, intraMUSCULAR, Once, Starting when released 2 Total injections in series. Verify 2nd dose is at least 8 weeks apart from 1st dose.				
☒	meningococcal B Vaccine (BEXSERO) injection	Once	S	1 treatment
0.5 mL, intraMUSCULAR, Once, Starting when released Do not mix with any other vaccine or product in the same syringe. Prior to administration, clean skin over the injection site with a suitable cleansing agent. Vigorously shake the prefilled syringe prior to administration to ensure a homogenous white suspension; DO NOT administer if the vaccine cannot be re-suspended. The preferred injection site is the deltoid muscle of the upper arm; do NOT inject into the gluteal area or other areas where there may be a major nerve trunk. 2 Total injections in series. Verify 2nd dose is at least 4 weeks apart from 1st dose.				
☒	pneumococcal 13-valent conjugate (PREVNAR 13) vaccine injection	Once	S	1 treatment
0.5 mL, intraMUSCULAR, Once, Starting when released Indicated for first 3 doses of pneumococcal vaccinations post HSCT. May use as 4th pneumococcal dose for patients with chronic GvHD.				
☒	haemophilus B polysac-tetanus toxoid (ActHIB/HIBERIX) injection 10 mcg	Once	S	1 treatment
0.5 mL, intraMUSCULAR, Once, Starting when released				
☒	SJH ONCBCN THERAPY SPLENECTOMY VACCINES DAY 57			
☒	meningococcal A conjugate vaccine (MENVEO) injection 0.5 mL	Once	S+56	1 treatment
0.5 mL, intraMUSCULAR, Once, Starting when released 2 Total injections in series. Verify 2nd dose is at least 8 weeks apart from 1st dose.				
☒	meningococcal B Vaccine (BEXSERO) injection	Once	S+56	1 treatment

Interval

Defer Until

Duration

0.5 mL, intraMUSCULAR, Once, Starting when released

Do not mix with any other vaccine or product in the same syringe.

Prior to administration, clean skin over the injection site with a suitable cleansing agent.

Vigorously shake the prefilled syringe prior to administration to ensure a homogenous white suspension; DO NOT administer if the vaccine cannot be re-suspended.

The preferred injection site is the deltoid muscle of the upper arm; do NOT inject into the gluteal area or other areas where there may be a major nerve trunk.

2 Total injections in series.

Verify 2nd dose is at least 4 weeks apart from 1st dose.



pneumococcal vaccine (PNEUMOVAX 23) syringe 0.5 mL

Once

S+56

1 treatment

0.5 mL, intraMUSCULAR, Once, Starting when released